Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
Year: 2022
Type: article
Study design: Observational Study
Source: Blood
Authors: Michael Scordo, Jessica R. Flynn, Sean M. Devlin, Mithat Gonen, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph E. Maakaron, Richard T. Maziarz, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Hospital General Universitario Gregorio Marañón, University of Pennsylvania, Abramson Cancer Center, University of Minnesota, Masonic Cancer Center, University of Minnesota Medical Center, Oregon Health & Science University, The University of Texas MD Anderson Cancer Center, University of Kansas Medical Center, Vanderbilt University Medical Center, Hackensack University Medical Center, University of Chicago
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310118122